<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761176</url>
  </required_header>
  <id_info>
    <org_study_id>RGI-08-08-1</org_study_id>
    <nct_id>NCT00761176</nct_id>
  </id_info>
  <brief_title>A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers</brief_title>
  <official_title>A Controlled Study Comparing Basic Wound Care to the Provant® Therapy System as an Adjunct to Basic Wound Care for Wound Surface Area Reduction in Diabetic Plantar Foot Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenesis Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenesis Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the reduction in wound surface areas between
      patients with diabetic ulcers utilizing Provant's pulsed radio frequency energy therapy
      (PRFE) as an adjunct to standardized basic wound care to those utilizing standardized basic
      wound care alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the American Diabetes Association (ADA), there are approximately 20.8 million
      people in the US with diabetes or 7% of the population (1). A significant number of the
      diabetic population is prone to pedal ulceration and estimates reveal that 15-20% of this
      population will develop a foot ulcer in their lifetime.

      Treatment of diabetic foot ulcerations have posed a problem to healthcare providers for many
      years. The literature describes many different modalities for direct wound treatment
      strategies. Most of these treatments rely on the timely application of biological dressings,
      offloading of the wound, regular (and often inconvenient) visits to the doctor, and most
      important, compliance by the patient. It is not uncommon for such wounds to be present for
      greater than six months, despite use of debridement, off-loading and other basic wound care
      techniques, before presenting for advanced therapy.

      Provant has been selected for study because:

        -  It is already indicated for the adjunctive palliative treatment of postoperative pain
           and edema in superficial soft tissue.

        -  It is a non-invasive wound treatment system which utilizes a proprietary PRFE signal
           which is hypothesized to trigger the release of endogenous growth factors that induce
           mitosis through accelerating the cell cycle, using a Ca+2 mediated pathway. The result
           is a significant increase in the rate of cell replication.

        -  It has also been shown that PRFE triggers a genetic sequence or cascade of 'wound
           repair' genes critical for the four stages of wound healing: inflammation, granulation,
           epithelialization, and remodeling.

        -  It has been utilized in the VA Health System since 2004 with no serious adverse events
           attributable to the device.

      This study will assess as an endpoints:

        -  Primary - the incidence of wounds reaching complete closure, and

        -  Secondary - the time to complete wound closure percentage reduction in wound area,
           percentage reduction in wound volume, and rate of healing mm2/day and mm3/day.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol Violations noted for 6 of 8 patients
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of Wounds Reaching Complete Closure</measure>
    <time_frame>approximate one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care will be utilized without the device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The Provant Therapy System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Thirty minutes, twice daily treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Provant Therapy System</intervention_name>
    <description>The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.</description>
    <arm_group_label>The Provant Therapy System</arm_group_label>
    <other_name>Radio frequency generator devices</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females &gt; 18 years of age

          2. History of Type 1 or 2 Diabetes Mellitus

          3. A diabetic plantar foot wound, Wagner grade 1 or 2 (See Exclusion Criteria, number
             four (4).

          4. The qualifying wound must have been present for ≥ 30 days; (the age of the wound will
             be recorded) based on patient history or documentation in the medical record.

          5. Ankle Brachial Index (ABI) score ≥ 0.7 and ≤ 1.2 with present palpable posterior
             tibial pulse or dorsalis pedis pulse in index foot

          6. Wound surface area ≥ 1.0 cm2 and ≤ 16.0 cm2

          7. Female subjects of childbearing age will be expected to test negative after taking a
             serum pregnancy test. Additionally, they must be willing to use an adequate and
             reliable method of contraception for the study duration. Females who are
             postmenopausal must have been postmenopausal at least one year or twelve months.

        Exclusion Criteria:

          1. Glycosylated Hemoglobin (HbA1c) greater than 12 within 30 days of enrollment

          2. Absent pedal Doppler signals in the foot with the index wound or the presence of
             significant peripheral artery disease ,

          3. Concurrent treatment of the index wound with another advanced wound care device (i.e.
             negative pressure wound therapy, non-contact ultrasound, hyperbaric oxygen, electrical
             stimulation) or pharmaceutical (e.g. growth factors) within thirty (30) days of
             enrollment.

          4. Index wounds with exposed muscle, ligament or tendon, or which probe to bone
             regardless of classification—See Inclusion Criteria no. two ( 2).

          5. Wounds due to a nondiabetic etiology (e.g. venous stasis, arterial insufficiency,
             etc.)

          6. Cellulitis, osteomyelitis, or other clinical evidence of infection involving the index
             wound.

          7. History of malignancy

          8. Concurrent use of high dose immunosuppressant or cytotoxic drugs

          9. Implanted pacemaker or defibrillator

         10. Metallic implant involving the index foot or ankle

         11. Implanted system with a metallic lead

         12. Pregnant or lactating females

         13. Concurrent participation in another clinical trial. 14) An unwillingness of the
             patient to comply with the study procedures and the required follow-up regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Wilson, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winston - Salem Outpatient Clinic, WG Hefner VAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winston - Salem Outpatient Clinic</name>
      <address>
        <city>Winston - Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <results_first_submitted>October 26, 2015</results_first_submitted>
  <results_first_submitted_qc>November 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2016</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Ulcers</keyword>
  <keyword>Wounds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>standardized care will be used for wound care on patients randomized to this arm.</description>
        </group>
        <group group_id="P2">
          <title>Active</title>
          <description>Provant Therapy Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>The Provant Wound Therapy System: The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Standardized wound care is used</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Incidence of Wounds Reaching Complete Closure</title>
        <time_frame>approximate one year</time_frame>
        <population>Analysis was not done as this study was early terminated due to all subjects not meeting inclusion/exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of Care will be utilized without the device.</description>
          </group>
          <group group_id="O2">
            <title>Active Provant Device</title>
            <description>Active Device
The Provant Wound Therapy System: The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Wounds Reaching Complete Closure</title>
          <population>Analysis was not done as this study was early terminated due to all subjects not meeting inclusion/exclusion criteria.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>standardized care will be used for wound care on patients randomized to this arm.</description>
        </group>
        <group group_id="E2">
          <title>Active</title>
          <description>Provant Therapy Device</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP of Clinical Research and Regulatory</name_or_title>
      <organization>Regenesis Biomedical, Inc.</organization>
      <phone>602-309-2118</phone>
      <email>mark.davis@regenesisbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

